Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERC NASDAQ:CRBP NASDAQ:HROW NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$14.41-9.5%$2.60$1.98▼$4.50$1.38B1.441.27 million shs1.58 million shsCRBPCorbus Pharmaceuticals$8.18-3.3%$9.41$6.72▼$20.56$156.74M2.57543,178 shs406,893 shsHROWHarrow$42.68-0.2%$36.91$28.54▼$54.85$1.59B0.28769,038 shs793,721 shsMNOVMediciNova$1.33-2.2%$1.36$1.17▼$1.96$66.94M0.6252,713 shs28,607 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor0.00%0.00%0.00%+3.30%+200.84%CRBPCorbus Pharmaceuticals-3.31%+1.61%-27.93%-11.47%+2.76%HROWHarrow-0.23%+1.76%+29.33%+20.63%+34.59%MNOVMediciNova-2.21%-0.75%-5.00%-6.34%-2.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$14.41-9.5%$2.60$1.98▼$4.50$1.38B1.441.27 million shs1.58 million shsCRBPCorbus Pharmaceuticals$8.18-3.3%$9.41$6.72▼$20.56$156.74M2.57543,178 shs406,893 shsHROWHarrow$42.68-0.2%$36.91$28.54▼$54.85$1.59B0.28769,038 shs793,721 shsMNOVMediciNova$1.33-2.2%$1.36$1.17▼$1.96$66.94M0.6252,713 shs28,607 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor0.00%0.00%0.00%+3.30%+200.84%CRBPCorbus Pharmaceuticals-3.31%+1.61%-27.93%-11.47%+2.76%HROWHarrow-0.23%+1.76%+29.33%+20.63%+34.59%MNOVMediciNova-2.21%-0.75%-5.00%-6.34%-2.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERCCerecor 0.00N/AN/AN/ACRBPCorbus Pharmaceuticals 2.75Moderate Buy$40.67397.15% UpsideHROWHarrow 2.64Moderate Buy$69.4362.67% UpsideMNOVMediciNova 2.67Moderate Buy$8.33526.57% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, CRBP, CERC, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $34.006/17/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$54.00 ➝ $52.005/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.005/26/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CRBPCorbus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/22/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $44.005/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERCCerecor$6.70M206.49N/AN/A$0.22 per share65.50CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/AHROWHarrow$272.30M5.84$0.86 per share49.50$1.41 per share30.27MNOVMediciNova$410K159.66N/AN/A$0.85 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ACRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A19.76N/A-5.57%19.59%2.26%8/10/2026 (Estimated)MNOVMediciNova-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%8/13/2026 (Estimated)Latest MNOV, CRBP, CERC, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNOVMediciNova-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCERCCerecorN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERCCerecor0.792.192.18CRBPCorbus PharmaceuticalsN/A7.927.92HROWHarrow10.302.482.30MNOVMediciNovaN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERCCerecor62.84%CRBPCorbus Pharmaceuticals64.64%HROWHarrow72.76%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipCERCCerecor45.70%CRBPCorbus Pharmaceuticals3.50%HROWHarrow12.80%MNOVMediciNova14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERCCerecor3196.01 millionN/ANot OptionableCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableHROWHarrow18037.28 million32.50 millionOptionableMNOVMediciNova1049.22 million42.33 millionOptionableMNOV, CRBP, CERC, and HROW HeadlinesRecent News About These CompaniesMediciNova Shareholders Reject Proposal to Increase Authorized StockJune 24 at 5:10 PM | tipranks.comMNOV Share News TodayJune 21, 2026 | uk.investing.comMediciNova (MNOV) Stock Forecast & Price TargetJune 11, 2026 | investing.comMediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentJune 8, 2026 | finanznachrichten.deMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentJune 8, 2026 | globenewswire.comMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical ...May 26, 2026 | caledonianrecord.comCMediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes May 26, 2026 | quiverquant.comQMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)May 26, 2026 | globenewswire.comMediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO StudyApril 27, 2026 | quiverquant.comQNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationApril 27, 2026 | globenewswire.comHC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendationMarch 17, 2026 | msn.comMediciNova to Participate at the 38th Annual ROTH ConferenceMarch 16, 2026 | globenewswire.comMediciNova: Q4 Earnings SnapshotFebruary 20, 2026 | wtop.comWMediciNova (MNOV) price target increased by 28.57% to 9.18February 4, 2026 | msn.comMediciNova Reports 100 Patient Enrollment in SEANOBI Study for MN-166 (Ibudilast) in ALS TreatmentJanuary 29, 2026 | quiverquant.comQMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsJanuary 29, 2026 | globenewswire.comMediciNova, Inc.: 2026 New Year's Greetings from the CEOJanuary 7, 2026 | finanznachrichten.de2026 New Year’s Greetings from the CEOJanuary 7, 2026 | finance.yahoo.comMediciNova issues letter to shareholdersJanuary 7, 2026 | msn.com2026 New Year's Greetings from the CEOJanuary 6, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, CRBP, CERC, and HROW Company DescriptionsCerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Corbus Pharmaceuticals NASDAQ:CRBP$8.18 -0.28 (-3.31%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$8.24 +0.05 (+0.67%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Harrow NASDAQ:HROW$42.68 -0.10 (-0.23%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$43.50 +0.81 (+1.91%) As of 05:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.MediciNova NASDAQ:MNOV$1.33 -0.03 (-2.21%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.33 0.00 (0.00%) As of 06/24/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
